{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:21Z","timestamp":1788419781775,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Inherited retinal dystrophies (IRDs) represent heterogeneous genetic eye disorders frequently linked to\n                    <jats:italic>RPE65<\/jats:italic>\n                    mutations. Voretigene neparvovec (VN, Luxturna), an AAV2-mediated gene therapy, remains the sole approved drug for biallelic\n                    <jats:italic>RPE65<\/jats:italic>\n                    -associated IRDs. This study presents 3-, 6- and 22-month follow-up findings of the first mainland Chinese patient with compound heterozygous\n                    <jats:italic>RPE65<\/jats:italic>\n                    -related Leber congenital amaurosis type 2 (LCA2) receiving sequential bilateral subretinal Luxturna injections. Binocular full-field stimulus threshold (FST) improvement was documented, and rod-dominant visual function improvement was verified via chromatic threshold difference analysis. No treatment-related adverse events were noted at the 3-month follow-up, while bilateral chorioretinal atrophic lesions, classified as treatment-emergent ocular findings with undetermined causal correlation to gene therapy, were detected at the 6-month visit, and these lesions further enlarged at the 22-month follow-up. Long-term assessment confirmed persistent improvement in dark-adapted visual function but not best-corrected visual acuity (BCVA). This single case demonstrates the favorable sustained dark-adapted rod function improvement of voretigene neparvovec in this Han Chinese patient with LCA2. Although obvious improvement in nyctalopia after early gene therapy has been observed in this patient, all FST data in this study are binocular integrated measurements that cannot be separated to evaluate individual monocular function. Further controlled cohort studies enrolling more Han Chinese participants are still required to verify whether early intervention provides more prominent and definitive relief of nyctalopia for patients carrying biallelic\n                    <jats:italic>RPE65<\/jats:italic>\n                    variants.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1888954","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:04Z","timestamp":1788417784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Ren","sequence":"first","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]},{"name":"He University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Rong","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Aier Eye Hospital, Aier Eye Hospital Group Co. Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoshi","family":"Wang","sequence":"additional","affiliation":[{"name":"He University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijing","family":"Pang","sequence":"additional","affiliation":[{"name":"Shenyang He Eye Specialist Hospital","place":["Shenyang, China"]},{"name":"He University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cell.2018.03.021","article-title":"Gene therapy for retinal degeneration","volume":"173","author":"Apte","year":"2018","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.9.11.9","article-title":"The RUSH2A study: best-corrected visual acuity, full-field electroretinography amplitudes, and full-field stimulus thresholds at baseline","volume":"9","author":"Birch","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/ejhg.2011.86","article-title":"A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement","volume":"19","author":"Bowne","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15112","DOI":"10.1073\/pnas.0807027105","article-title":"Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics","volume":"105","author":"Cideciyan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/1531-8249(199904)45:4<451::aid-ana6>3.0.co;2-b","article-title":"Period of susceptibility for cross-modal plasticity in the blind","volume":"45","author":"Cohen","year":"1999","journal-title":"Ann. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.xops.2026.101090","article-title":"Expert consensus on characteristics, etiology, and management of chorioretinal atrophy in patients treated with voretigene neparvovec","volume":"6","author":"Fischer","year":"2026","journal-title":"Ophthalmol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-Mediated leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"B8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13023-021-01807-3","article-title":"Frequency and phenotypic characteristics of RPE65 mutations in the Chinese population","volume":"16","author":"Gao","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"101244","DOI":"10.1016\/j.preteyeres.2024.101244","article-title":"Phenotyping and genotyping inherited retinal diseases: molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, leber congenital amaurosis, and cone dysfunction syndromes","volume":"100","author":"Georgiou","year":"2024","journal-title":"Prog. Retin Eye Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1113\/jphysiol.1970.sp009022","article-title":"The period of susceptibility to the physiological effects of unilateral eye closure in kittens","volume":"206","author":"Hubel","year":"1970","journal-title":"J. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10633-023-09962-7","article-title":"ISCEV and IPS guideline for the full-field stimulus test (FST)","volume":"148","author":"Jolly","year":"2024","journal-title":"Doc. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40291-020-00475-6","article-title":"Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy","volume":"24","author":"Kang","year":"2020","journal-title":"Mol. Diagn Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are We, and how did we get here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/bjophthalmol-2016-309975","article-title":"Leber congenital amaurosis\/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions","volume":"101","author":"Kumaran","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-neuro-061010-113813","article-title":"Critical-period plasticity in the visual cortex","volume":"35","author":"Levelt","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"key":"B17","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"B18","first-page":"267","article-title":"Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye","volume":"15","author":"Li","year":"2009","journal-title":"Mol. Vis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/iovs.10-6138","article-title":"Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis","volume":"52","author":"Li","year":"2011","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1291795","DOI":"10.3389\/fmed.2023.1291795","article-title":"Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis","volume":"10","author":"Liu","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B21","volume-title":"LUXTURNA","year":"2017"},{"key":"B22","volume-title":"LUXTURNA","year":"2026"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/tvst.14.8.8","article-title":"Short-term outcomes of pediatric patients with mild autosomal recessive RPE65-Associated retinal dystrophy treated with voretigene neparvovec","volume":"14","author":"Merle","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B24","volume-title":"Novartis Announces Landmark EU Approval for one-time Gene Therapy Luxturna\u00ae to Restore Vision in People with Rare Inherited Retinal Disease","year":"2018"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1016\/j.visres.2006.05.010","article-title":"Cortical visual function in the rd12 mouse model of leber congenital amarousis (LCA) after gene replacement therapy to restore retinal function","volume":"46","author":"Nusinowitz","year":"2006","journal-title":"Vis. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ymthe.2005.09.001","article-title":"Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis","volume":"13","author":"Pang","year":"2006","journal-title":"Mol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/gt.2010.29","article-title":"Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency","volume":"17","author":"Pang","year":"2010","journal-title":"Gene Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/08164622.2024.2349565","article-title":"Non-invasive brain stimulation and vision rehabilitation: a clinical perspective","volume":"107","author":"Park","year":"2024","journal-title":"Clin. Exp. Optom."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1073\/pnas.91.4.1206","article-title":"Spatial interactions in human vision: from near to far via experience-dependent cascades of connections","volume":"91","author":"Polat","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1073\/pnas.0401200101","article-title":"Improving vision in adult amblyopia by perceptual learning","volume":"101","author":"Polat","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.brs.2020.12.015","article-title":"Reduction of collinear inhibition in observers with central vision loss using anodal transcranial direct current stimulation: a case series","volume":"14","author":"Raveendran","year":"2021","journal-title":"Brain Stimul."},{"key":"B32","volume-title":"RetNet: Summaries of Genes and Loci Causing Retinal Diseases","year":"2026"},{"key":"B33","doi-asserted-by":"publisher","first-page":"101000","DOI":"10.1016\/j.preteyeres.2021.101000","article-title":"Full-field stimulus testing: role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease","volume":"87","author":"Roman","year":"2022","journal-title":"Prog. Retin Eye Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41598-024-53474-6","article-title":"Relationship between residual visual field and full-field stimulus testing in patients with late-stage retinal degenerative diseases","volume":"14","author":"Sakai","year":"2024","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000549548","article-title":"Chorioretinal atrophy after voretigene Neparvovec therapy in RPE65 mutation-associated inherited retinal disease: longitudinal characterization in multimodal imaging","volume":"249","author":"Sassen","year":"2026","journal-title":"Ophthalmologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.survophthal.2021.08.008","article-title":"Electrical devices for visual restoration","volume":"67","author":"Sharf","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41433-023-02636-3","article-title":"Full-field stimulus threshold testing: a scoping review of current practice","volume":"38","author":"Shi","year":"2024","journal-title":"Eye (Lond)."},{"key":"B39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/15569527.2025.2573463","article-title":"Clinical and pharmacovigilance safety evaluation of LUXTURNA(\u00ae) (voretigene neparvovec-rzyl)","volume":"44","author":"Simoens","year":"2025","journal-title":"Cutan. Ocul. Toxicol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene Neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/tvst.13.2.13","article-title":"Chorioretinal atrophy growth after voretigene neparvovec retinotopically is connected to retinal functional rescue","volume":"13","author":"Stingl","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B42","first-page":"4293","article-title":"Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration","volume":"41","author":"Thompson","year":"2000","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1167\/iovs.14-16049","article-title":"Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the monaciano symposium","volume":"56","author":"Thompson","year":"2015","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1146\/annurev.pharmtox.47.120505.105225","article-title":"Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents","volume":"47","author":"Travis","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/tvst.14.11.24","article-title":"Mild RPE65-Associated inherited retinal dystrophies: a multimodal clinical and genetic evaluation","volume":"14","author":"Wolfram","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms20225722","article-title":"Gene therapy in retinal dystrophies","volume":"20","author":"Ziccardi","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1888954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:07Z","timestamp":1788417787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1888954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":46,"alternative-id":["10.3389\/fphar.2026.1888954"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1888954","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1888954"}}